Search Results - "Newhall, Kathryn"

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk by Harrington, Kimberly H, Gudgeon, Chelsea J, Laszlo, George S, Newhall, Kathryn J, Sinclair, Angus M, Frankel, Stanley R, Kischel, Roman, Chen, Guang, Walter, Roland B

“…The CD33/CD3-bispecific T-cell engaging (BiTE) antibody construct, AMG 330, potently lyses CD33+ leukemic cells in vitro. Using specimens from 41 patients with…”
Get full text

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML by Laszlo, George S., Gudgeon, Chelsea J., Harrington, Kimberly H., Dell'Aringa, Justine, Newhall, Kathryn J., Means, Gary D., Sinclair, Angus M., Kischel, Roman, Frankel, Stanley R., Walter, Roland B.

“…CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we investigated the cellular…”
Get full text

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma by Young, Mary H., Pietz, Greg, Whalen, Elizabeth, Copeland, Wilbert, Thompson, Ethan, Fox, Brian A., Newhall, Kathryn J.

“…This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell…”
Get full text

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel by Olson, N Eric, Ragan, Seamus P, Reiss, David J, Thorpe, Jerill, Kim, Yeonhee, Abramson, Jeremy S, McCoy, Candice, Newhall, Kathryn J, Fox, Brian A

“…In the TRANSCEND NHL 001 study, 53% of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved…”
Get full text

Mutations Affecting the SAND Domain of DEAF1 Cause Intellectual Disability with Severe Speech Impairment and Behavioral Problems by Vulto-van Silfhout, Anneke T., Rajamanickam, Shivakumar, Jensik, Philip J., Vergult, Sarah, de Rocker, Nina, Newhall, Kathryn J., Raghavan, Ramya, Reardon, Sara N., Jarrett, Kelsey, McIntyre, Tara, Bulinski, Joseph, Ownby, Stacy L., Huggenvik, Jodi I., McKnight, G. Stanley, Rose, Gregory M., Cai, Xiang, Willaert, Andy, Zweier, Christiane, Endele, Sabine, de Ligt, Joep, van Bon, Bregje W.M., Lugtenberg, Dorien, de Vries, Petra F., Veltman, Joris A., van Bokhoven, Hans, Brunner, Han G., Rauch, Anita, de Brouwer, Arjan P.M., Carvill, Gemma L., Hoischen, Alexander, Mefford, Heather C., Eichler, Evan E., Vissers, Lisenka E.L.M., Menten, Björn, Collard, Michael W., de Vries, Bert B.A.

“…Recently, we identified in two individuals with intellectual disability (ID) different de novo mutations in DEAF1, which encodes a transcription factor with an…”
Get full text

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients by Frerichs, Kristine A., Verkleij, Christie P. M., Dimopoulos, Meletios A., Marin Soto, Jhon A., Zweegman, Sonja, Young, Mary H., Newhall, Kathryn J., Mutis, Tuna, van de Donk, Niels W. C. J.

“…Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will…”
Get full text

Dynamic Anchoring of PKA Is Essential during Oocyte Maturation by Newhall, Kathryn J., Criniti, Amy R., Cheah, Christine S., Smith, Kimberly C., Kafer, Katherine E., Burkart, Anna D., McKnight, G. Stanley

“…In the final stages of ovarian follicular development, the mouse oocyte remains arrested in the first meiotic prophase, and cAMP-stimulated PKA plays an…”
Get full text

Evidence for Endotoxin Contamination in Plastic Na+-Heparin Blood Collection Tube Lots by NEWHALL, Kathryn J, DIEMER, Geoffrey S, LESHINSKY, Natalia, KERKOF, Keith, CHUTE, Hilary T, RUSSELL, Chris B, REES, William, WELCHER, Andrew A, PATTERSON, Scott D, MEANS, Gary D

“…Biomarker assays are often conducted on whole blood samples in the course of drug development studies. Because bacterial lipopolysaccharide (LPS) (endotoxin)…”
Get full text

Mutations Affecting the SAND Domain of DEAF1 Cause Intellectual Disability with Severe Speech Impairment and Behavioral Problems by Vulto-van Silfhout, Anneke T., Rajamanickam, Shivakumar, Jensik, Philip J., Vergult, Sarah, de Rocker, Nina, Newhall, Kathryn J., Raghavan, Ramya, Reardon, Sara N., Jarrett, Kelsey, McIntyre, Tara, Bulinski, Joseph, Ownby, Stacy L., Huggenvik, Jodi I., McKnight, G. Stanley, Rose, Gregory M., Cai, Xiang, Willaert, Andy, Zweier, Christiane, Endele, Sabine, de Ligt, Joep, van Bon, Bregje W.M., Lugtenberg, Dorien, de Vries, Petra F., Veltman, Joris A., van Bokhoven, Hans, Brunner, Han G., Rauch, Anita, de Brouwer, Arjan P.M., Carvill, Gemma L., Hoischen, Alexander, Mefford, Heather C., Eichler, Evan E., Vissers, Lisenka E.L.M., Menten, Björn, Collard, Michael W., de Vries, Bert B.A.

Get full text

Deletion of the RIIβ-Subunit of Protein Kinase A Decreases Body Weight and Increases Energy Expenditure in the Obese, Leptin-Deficient ob/ob Mouse by Newhall, Kathryn J, Cummings, David E, Nolan, Michael A, McKnight, G. Stanley

“…Disruption of the RIIβ regulatory subunit of protein kinase A (PKA) results in mice with a lean phenotype, nocturnal hyperactivity, and increased resting…”
Get full text

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study by Abramson, Jeremy S, Palomba, M Lia, Gordon, Leo I, Lunning, Matthew A, Wang, Michael, Arnason, Jon, Mehta, Amitkumar, Purev, Enkhtsetseg, Maloney, David G, Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R, Ghosh, Nilanjan, Albertson, Tina M, Garcia, Jacob, Kostic, Ana, Mallaney, Mary, Ogasawara, Ken, Newhall, Kathryn, Kim, Yeonhee, Li, Daniel, Siddiqi, Tanya

“…Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety…”
Get full text

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies by Ogasawara, Ken, Newhall, Kathryn, Maxwell, Stephen E., Dell’Aringa, Justine, Komashko, Vitalina, Kilavuz, Nurgul, Delarue, Richard, Czuczman, Myron, Sternas, Lars, Rose, Shelonitda, Beach, C. L., Novick, Steven, Zhou, Simon, Palmisano, Maria, Li, Yan

“…Background and Objectives Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and…”
Get full text

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) by Abramson, Jeremy S., Ramakrishnan, Aravind, Pierola, Ana Alfonso, Braunschweig, Ira, Cartron, Guillaume, Thieblemont, Catherine, Pérez-Simón, Jose A., Barba, Pere, Riedell, Peter A., Solano, Carlos, Gastinne, Thomas, LaCroce, Alexandra, Thomas, Denise, Poirot, Camille, Meadows, Sarah, Newhall, Kathryn J., Lee, Daniel J., Frattini, Mark G., Bachy, Emmanuel

“…Background: UCART20x22 is a dual targeted allogeneic CAR T-cell product candidate generated from healthy donor T-cells. Donor-derived T-cells are transduced…”
Get full text

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) by Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., Boissel, Nicolas

“…Introduction: UCART22 is a genetically modified allogeneic T-cell product manufactured from healthy donor cells. Donor-derived T-cells are transduced using a…”
Get full text

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns by Huang, C. Chris, Nakayama, Yumi, Stokes, Matthew, Towfic, Fadi, Lee, chung-Wein, Ren, Yan, Marella, Mathieu, Wang, Maria, Hagner, Patrick R., Couto, Suzana, Newhall, Kathryn, Gandhi, Anita K

“…Background: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease of malignant B cells most often classified by tumor gene expression…”
Get full text

Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001 by Abramson, Jeremy S., Palomba, Maria Lia, Arnason, Jon E., Lunning, Matthew Alexander, Solomon, Scott R., Farazi, Thalia, Garcia, Jacob, Xie, Benhuai, Newhall, Kathryn J., Dehner, Christine, Siddiqi, Tanya

“…Abstract only 7515 Background: No clinical studies have yet evaluated CAR T cell therapies in pts with R/R B-cell NHL who have secondary CNS lymphoma. We…”
Get full text

Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response by Reiss, David J., Do, Trevor, Kuo, David, Gray, Vanessa E., Olson, N. Eric, Lee, Chung-Wein, Young, Mary H., Srinivasan, Shradha, Gray, Falon D., Fox, Brian, Couto, Suzana, Dubovsky, Jason A., Schmitz, Frank, Newhall, Kathryn

“…Background: The availability of chimeric antigen receptor (CAR)-modified T cells (CAR T) has profoundly increased therapeutic options for patients (pts) with B…”
Get full text

Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001 by Wang, Michael, Gordon, Leo I., Palomba, Maria Lia, Abramson, Jeremy S., Andreadis, Charalambos, Ghosh, Nilanjan, Lunning, Matthew Alexander, Maloney, David G., Farazi, Thalia Andrea, Garcia, Jacob, Xie, Benhuai, Newhall, Kathryn J., Dehner, Christine, Siddiqi, Tanya

“…Abstract only 7516 Background: Most pts with MCL relapse after first-line immunochemotherapy, with poor responses to salvage therapy. We report initial…”
Get full text

Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status by Pietz, Greg E., Tometsko, Mark, Copeland, Wilbert B., Whalen, Elizabeth, Schmitz, Frank, Thompson, Ethan G., Agarwal, Amit, Foy, Teresa, Buchholz, Lauren, Komashko, Vitalina, Dell'Aringa, Justine, Fox, Brian A., Newhall, Kathryn

“…Loss of immune surveillance is critical in the pathogenesis of multiple myeloma (MM) and the progression from smoldering to symptomatic MM. To date, no clear…”
Get full text

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial by Casulo, Carla, Santoro, Armando, Ando, Kiyoshi, Le Gouill, Steven, Ruan, Jia, Radford, John, Arcaini, Luca, Pinto, Antonello, Bouabdallah, Reda, Izutsu, Koji, Rule, Simon, Munoz, Javier, Casadebaig, Marie-Laure, Fox, Brian, Rettby, Nils, Dell'Aringa, Justine, Delarue, Richard, Newhall, Kathryn, Czuczman, Myron, Cartron, Guillaume

“…Introduction: Targeting immune cells in the tumor microenvironment is an attractive approach to improving antitumor activity of standard therapy in r/r…”
Get full text